Prestige Consumer Healthcare Management
Management criteria checks 4/4
Prestige Consumer Healthcare's CEO is Ron Lombardi, appointed in Jun 2015, has a tenure of 9.67 years. total yearly compensation is $5.76M, comprised of 17.4% salary and 82.6% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth $22.16M. The average tenure of the management team and the board of directors is 8.3 years and 4.8 years respectively.
Key information
Ron Lombardi
Chief executive officer
US$5.8m
Total compensation
CEO salary percentage | 17.4% |
CEO tenure | 9.7yrs |
CEO ownership | 0.6% |
Management average tenure | 8.3yrs |
Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Feb 07Pinning Down Prestige Consumer Healthcare Inc.'s (NYSE:PBH) P/S Is Difficult Right Now
Jan 16Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 45% Below Their Intrinsic Value Estimate
Dec 04We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Nov 03Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Popularity With Investors Is Under Threat From Overpricing
Sep 10Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Jul 16Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
May 22Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Nov 04CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2024 | n/a | n/a | US$214m |
Sep 30 2024 | n/a | n/a | US$206m |
Jun 30 2024 | n/a | n/a | US$205m |
Mar 31 2024 | US$6m | US$1m | US$209m |
Dec 31 2023 | n/a | n/a | -US$81m |
Sep 30 2023 | n/a | n/a | -US$82m |
Jun 30 2023 | n/a | n/a | -US$84m |
Mar 31 2023 | US$6m | US$1m | -US$82m |
Dec 31 2022 | n/a | n/a | US$210m |
Sep 30 2022 | n/a | n/a | US$209m |
Jun 30 2022 | n/a | n/a | US$203m |
Mar 31 2022 | US$6m | US$937k | US$205m |
Dec 31 2021 | n/a | n/a | US$189m |
Sep 30 2021 | n/a | n/a | US$179m |
Jun 30 2021 | n/a | n/a | US$179m |
Mar 31 2021 | US$5m | US$888k | US$165m |
Dec 31 2020 | n/a | n/a | US$166m |
Sep 30 2020 | n/a | n/a | US$163m |
Jun 30 2020 | n/a | n/a | US$152m |
Mar 31 2020 | US$5m | US$875k | US$142m |
Dec 31 2019 | n/a | n/a | -US$34m |
Sep 30 2019 | n/a | n/a | -US$34m |
Jun 30 2019 | n/a | n/a | -US$36m |
Mar 31 2019 | US$4m | US$850k | -US$36m |
Dec 31 2018 | n/a | n/a | US$64m |
Sep 30 2018 | n/a | n/a | US$340m |
Jun 30 2018 | n/a | n/a | US$340m |
Mar 31 2018 | US$4m | US$850k | US$340m |
Compensation vs Market: Ron's total compensation ($USD5.76M) is about average for companies of similar size in the US market ($USD6.61M).
Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.
CEO
Ron Lombardi (60 yo)
9.7yrs
Tenure
US$5,763,133
Compensation
Mr. Ronald M. Lombardi, also known as Ron, served as a Director at Consumer Healthcare Products Association. He has been the Chief Executive Officer and President of Prestige Brands Holdings, Inc. (now Pre...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 9.7yrs | US$5.76m | 0.59% $ 22.2m | |
CFO & COO | 8.4yrs | US$2.00m | 0.036% $ 1.3m | |
Senior VP | 8.3yrs | US$1.34m | 0.026% $ 989.2k | |
Executive Vice President of Marketing & Sales | 5.8yrs | US$1.32m | 0.024% $ 920.8k | |
Senior Vice President of Operations | no data | US$862.93k | 0.064% $ 2.4m | |
Director of Investor Relations | no data | no data | no data | |
Director of Communications | no data | no data | no data | |
Senior Vice President of Quality & Regulatory Affairs | 6.7yrs | no data | 0.030% $ 1.1m |
8.3yrs
Average Tenure
60yo
Average Age
Experienced Management: PBH's management team is seasoned and experienced (8.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 9.7yrs | US$5.76m | 0.59% $ 22.2m | |
Lead Independent Director | 19.1yrs | US$273.33k | 0.097% $ 3.7m | |
Independent Director | 4yrs | US$257.08k | 0.014% $ 528.2k | |
Independent Director | 4.8yrs | US$260.63k | 0.020% $ 756.5k | |
Independent Director | 9.5yrs | US$243.33k | 0.048% $ 1.8m | |
Independent Director | 1.5yrs | US$197.92k | no data | |
Independent Director | less than a year | no data | no data |
4.8yrs
Average Tenure
63yo
Average Age
Experienced Board: PBH's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/06 08:39 |
End of Day Share Price | 2025/02/06 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prestige Consumer Healthcare Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Olivia Tong Cheang | BofA Global Research |
Linda Bolton-Weiser | B. Riley Securities, Inc. |
Susan Anderson | Canaccord Genuity |